http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#Head
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#assertion
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#provenance
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#pubinfo
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#assertion
http://purl.obolibrary.org/obo/DOID_9253
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_9253
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB01268
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association
http://www.w3.org/2000/01/rdf-schema#label
sutent is a kinase inhibitor indicated for the treatment of gastrointestinal stromal tumor gist after disease progression on or intolerance to imatinib mesylate 1 1 the treatment of advanced renal cell carcinoma rcc 1 2 the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy 1 3 the treatment of progressive well differentiated pancreatic neuroendocrine tumors pnet in patients with unresectable locally advanced or metastatic disease 1 4 sutent is indicated for the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate sutent is indicated for the treatment of advanced renal cell carcinoma sutent is indicated for the adjuvant treatment of adult patients at high risk of recurrent rcc following nephrectomy sutent is indicated for the treatment of progressive well differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#association
https://w3id.org/biolink/vocab/relation
https://schema.org/TreatmentIndication
https://identifiers.org/drugbank:DB01268
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#provenance
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#pubinfo
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#sig
http://purl.org/nanopub/x/hasSignature
W7evpAoZitylKf6XLlyxemxu4Yj4Qb2Uh7K4Elax2iDSZeCSjR6xY2Dr2RFon1dO65mpnh6bk2j4A7y+IaO4hA3fqOx8ZRyeF58QZkDhgMjxuGKS+Zw0LCAibOCvzFyc5tvJfbyQyQMROZv26BZc4V/sDnsWfDsmKaVeeruddfg=
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk
http://purl.org/dc/terms/created
2021-07-03T11:32:50.622+02:00
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAfTVJUyUhIedzaL4uEt2LZ6zbtNDQ7nhmv5IZNdrKyFk
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs